Biopharma firm Celgene ( CELG) is another stock that's posted some blockbuster performance numbers in 2013; this $66 billion drug maker has seen its shares more than double since the start of the year. But despite that breakneck performance, CELG is well-positioned for more upside before the year is over.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts